Suppr超能文献

亚洲特有的 CDKN2B 3'UTR 变异与垂体腺瘤风险相关。

Asian-specific 3'UTR variant in CDKN2B associated with risk of pituitary adenoma.

机构信息

Department of Life Science, Sogang University, 04107, Seoul, Republic of Korea.

Forensic DNA Division, National Forensic Service, 26460, Wonju, Republic of Korea.

出版信息

Mol Biol Rep. 2022 Nov;49(11):10339-10346. doi: 10.1007/s11033-022-07796-1. Epub 2022 Sep 12.

Abstract

BACKGROUND

Previous genomewide association studies (GWASs), single nucleotide polymorphisms (SNPs) on cyclin-dependent kinase inhibitor 2 A (CDKN2A), cyclin-dependent kinase inhibitor 2B (CDKN2B), and cyclin-dependent kinase inhibitor 2B antisense RNA1 (CDKN2B-AS1) were reported as risk loci for glioma, a subgroup of the brain tumor. To further characterize this association with the risk of brain tumors in a Korean population, we performed a fine-mapping association study of CDKN2A, CDKN2B, and CDKN2B-AS1.

METHODS AND RESULTS

A total of 17 SNPs were selected and genotyped in 1,439 subjects which were comprised of 959 patients (pituitary adenoma 335; glioma 324; meningioma 300) and 480 population controls (PCs). We discovered that a 3'untranslated region (3'UTR) variant, rs181031884 of CDKN2B (Asian-specific variant), had significant association with the risk of pituitary adenoma (PA) (Odds ratio = 0.58, P = 0.00003). Also, rs181031884 appeared as an independent causal variant among the significant variants in CDKN2A and CDKN2B, and showed dose-dependent effects on PA.

CONCLUSIONS

Although further studies are needed to verify the impact of this variant on PA susceptibility, our results may help to understand CDKN2B polymorphism and the risk of PA.

摘要

背景

先前的全基因组关联研究(GWAS)表明,细胞周期蛋白依赖性激酶抑制剂 2A(CDKN2A)、细胞周期蛋白依赖性激酶抑制剂 2B(CDKN2B)和细胞周期蛋白依赖性激酶抑制剂 2B 反义 RNA1(CDKN2B-AS1)上的单核苷酸多态性(SNP)是脑肿瘤(包括脑肿瘤亚组在内)的风险基因座。为了进一步描述这种与韩国人群脑肿瘤风险的关联,我们对 CDKN2A、CDKN2B 和 CDKN2B-AS1 进行了精细映射关联研究。

方法和结果

在由 959 名患者(垂体腺瘤 335 例;胶质瘤 324 例;脑膜瘤 300 例)和 480 名人群对照(PC)组成的 1439 名受试者中,共选择并检测了 17 个 SNP。我们发现 CDKN2B 的 3'非翻译区(3'UTR)变体 rs181031884(亚洲特异性变体)与垂体腺瘤(PA)的风险具有显著相关性(优势比=0.58,P=0.00003)。此外,rs181031884 是 CDKN2A 和 CDKN2B 中显著变体的独立因果变体,并且对 PA 表现出剂量依赖性效应。

结论

虽然需要进一步研究来验证该变体对 PA 易感性的影响,但我们的结果可能有助于理解 CDKN2B 多态性和 PA 风险。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验